Subclinical atrial fibrillation detected by implantable and wearable devices: a systematic review of diagnostic definitions and when to anticoagulate

Abstract

Subclinical atrial fibrillation detected by implantable cardiac devices and wearable technologies is associated with an increased risk of thromboembolic events. However, the decision to initiate oral anticoagulation remains controversial because absolute stroke risk varies and anticoagulant therapy increases major bleeding. Recent randomized clinical trials suggest stroke reduction at the expense of higher bleeding risk, supporting individualized, patient-centered decision-making.